Reports Q2 revenue $5.4B, consensus $5.41B. “We delivered another quarter of strong organic sales growth,” said Kevin Lobo, CEO. “We remain committed to our margin expansion goals and are excited about our product and M&A pipelines.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYK:
- SYK Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- SYK, ISRG, DXCM: Which “Strong Buy” Healthcare Stock Is the Best Bet?
- Stryker price target raised to $350 from $345 at Morgan Stanley
- Stryker price target raised to $372 from $369 at BTIG
- Stryker price target lowered to $365 from $370 at Evercore ISI